Needham Maintains Buy on Avrobio, Lowers Price Target to $8
Needham analyst Gil Blum maintains Avrobio (NASDAQ:AVRO) with a Buy and lowers the price target from $28 to $8.
Mid-Afternoon Market Update: Dow Jumps 250 Points; Avrobio Shares Slide
Toward the end of trading Tuesday, the Dow traded up 0.70% to 36,839.62 while the NASDAQ fell 1.57% to 15,583.77. The S&P also fell, dropping 0.03% to 4,794.93.
Mid-Day Market Update: Nasdaq Dips 250 Points; TherapeuticsMD Shares Surge
Midway through trading Tuesday, the Dow traded up 0.66% to 36,827.65 while the NASDAQ fell 1.63% to 15,574.50. The S&P also fell, dropping 0.08% to 4,792.93.
Stocks That Breached 52-Week Lows Today
Stocks That Managed to Breach 52-Week Lows Tuesday Morning
Before 10 am Tuesday, 44 stocks made new 52-week lows.
52-Week High And Low Highlights:
Block (NYSE: SQ) was the biggest company on a market cap basis to set aStocks That Managed to Breach 52-Week Lows Tuesday Morning
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Drops To 58.7
Following the market opening Tuesday, the Dow traded up 0.74% to 36,857.55 while the NASDAQ fell 0.14% to 15,811.30. The S&P also rose, gaining 0.40% to 4,815.75.
The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why Avrobio’s Shares Are Plunging Today
Avrobio Inc (NASDAQ: AVRO) has updated its pipeline deprioritizing its Fa
AVROBIO Announces Fabry Disease Program To Be Deprioritize, Co. ‘shifting focus to other clinical-stage programs in lysosomal disorder pipeline’
Fabry disease program to be deprioritized, shifting focus to other clinical-stage programs in lysosomal disorder pipeline
Data updates for cystinosis and Gaucher disease type 1 programs planned for 1H 2022, with
Morgan Stanley Downgrades Avrobio to Equal-Weight, Lowers Price Target to $7
Morgan Stanley analyst Michael Ulz downgrades Avrobio (NASDAQ:AVRO) from Overweight to Equal-Weight and lowers the price target from $24 to $7.